hexamethonium has been researched along with Cardiovascular Stroke in 11 studies
Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Some of this information includes: the unexpected yet very real hazards as well as benefits associated with the long-term use of powerful drugs, in particular the original description of hydralazine-induced lupus, its relation to genetic markers and its association with control of hypertension; the apparently decreasing need for antihypertensive drugs in subjects with well-controlled severe and moderate hypertension; the identification of risk factors for the complications of hypertension and the quantitation of their effects; the decrease in the incidence of hypertensive complications associated with the pharmacologic treatment of severe, moderate and, at least, the upper ranges of mild hypertension; the possibility of designing a chemical to block a specific reaction and the realization that it would have broader than expected effects; and the primary prevention of myocardial infarction in very high risk subjects." | 4.77 | The evolution of antihypertensive therapy. ( Perry, HM, 1985) |
| "Pretreatment with hexamethonium, a ganglion blocker (20 mg/kg, i." | 1.51 | Late Phases of Cardioprotection During Remote Ischemic Preconditioning and Adenosine Preconditioning Involve Activation of Neurogenic Pathway. ( Jaggi, AS; Kumar, M; Singh, H; Singh, N, 2019) |
| "Myocardial infarction is the leading cause of death worldwide." | 1.46 | Cardioprotection induced in a mouse model of neuropathic pain via anterior nucleus of paraventricular thalamus. ( Chang, YT; Chen, CC; Chen, WH; Chen, YH; Cheng, YF; Shih, HC; Shyu, BC, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 4 (36.36) | 29.6817 |
| 2010's | 3 (27.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, YF | 1 |
| Chang, YT | 1 |
| Chen, WH | 1 |
| Shih, HC | 1 |
| Chen, YH | 1 |
| Shyu, BC | 1 |
| Chen, CC | 1 |
| Singh, H | 1 |
| Kumar, M | 1 |
| Singh, N | 1 |
| Jaggi, AS | 1 |
| Kingma, JG | 1 |
| Simard, D | 1 |
| Voisine, P | 1 |
| Rouleau, JR | 1 |
| Wolfrum, S | 1 |
| Schneider, K | 1 |
| Heidbreder, M | 1 |
| Nienstedt, J | 1 |
| Dominiak, P | 1 |
| Dendorfer, A | 1 |
| Weinbrenner, C | 1 |
| Nelles, M | 1 |
| Herzog, N | 1 |
| Sárváry, L | 1 |
| Strasser, RH | 1 |
| OHYAMA, Y | 1 |
| AOKI, Y | 1 |
| TAMURA, K | 1 |
| KAWABE, A | 1 |
| IMAI, T | 1 |
| KIKUTA, R | 1 |
| EGUCHI, A | 1 |
| MASHIMA, T | 1 |
| OGURO, C | 1 |
| Manintveld, OC | 1 |
| te Lintel Hekkert, M | 1 |
| Keijzer, E | 1 |
| Verdouw, PD | 3 |
| Duncker, DJ | 3 |
| Freis, ED | 1 |
| Gho, BC | 1 |
| Schoemaker, RG | 1 |
| van den Doel, MA | 1 |
| Liem, DA | 1 |
| Ploeg, H | 1 |
| Kazim, S | 1 |
| Perry, HM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Controlled Trial of the Effect of Remote Ischaemic Conditioning on Coronary Endothelial Function in Patients With Angina.[NCT02666235] | Phase 2 | 60 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Cardiopulmonary Protection of Modified Remote Ischaemic Preconditioning in Mitral Valve Replacement Surgery[NCT03010839] | 86 participants (Actual) | Interventional | 2016-11-05 | Completed | |||
| Effect of Remote Ischemic Preconditioning on Pulmonary Injury in Cardic Surgery[NCT03016182] | 60 participants (Anticipated) | Interventional | 2017-02-07 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for hexamethonium and Cardiovascular Stroke
| Article | Year |
|---|---|
The evolution of antihypertensive therapy.
Topics: Antihypertensive Agents; Bis-Trimethylammonium Compounds; Blood Pressure; Calcium Channel Blockers; | 1985 |
10 other studies available for hexamethonium and Cardiovascular Stroke
| Article | Year |
|---|---|
Cardioprotection induced in a mouse model of neuropathic pain via anterior nucleus of paraventricular thalamus.
Topics: Animals; Butadienes; Chronic Pain; Disease Models, Animal; Enzyme Inhibitors; Ganglionic Blockers; H | 2017 |
Late Phases of Cardioprotection During Remote Ischemic Preconditioning and Adenosine Preconditioning Involve Activation of Neurogenic Pathway.
Topics: Adenosine; Animals; Autonomic Nervous System; Creatine Kinase; Disease Models, Animal; Ganglionic Bl | 2019 |
Role of the autonomic nervous system in cardioprotection by remote preconditioning in isoflurane-anaesthetized dogs.
Topics: Anesthesia, General; Anesthetics, Inhalation; Animals; Autonomic Denervation; Autonomic Nervous Syst | 2011 |
Remote preconditioning protects the heart by activating myocardial PKCepsilon-isoform.
Topics: Adrenergic beta-Antagonists; Alkaloids; Animals; Benzophenanthridines; Bradykinin; Enzyme Activation | 2002 |
Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-neuronal but PKC-dependent pathway.
Topics: Animals; Ganglionic Blockers; Hexamethonium; Hindlimb; Ischemic Preconditioning; Ischemic Preconditi | 2002 |
A CASE OF ACUTE MYOCARDIAL INFARCTION WITH INITIAL ST SEGMENT DEPRESSIN.
Topics: Abscess; Alanine Transaminase; Anal Canal; Arrhythmias, Cardiac; Aspartate Aminotransferases; Blood | 1964 |
Intravenous adenosine protects the myocardium primarily by activation of a neurogenic pathway.
Topics: Adenosine; Animals; Cardiotonic Agents; Ganglionic Blockers; Hexamethonium; Infusions, Intravenous; | 2005 |
Preload and afterload reduction in treating congestive heart failure.
Topics: Autonomic Nerve Block; Heart Failure; Hemodynamics; Hexamethonium; Hexamethonium Compounds; Humans; | 1984 |
Myocardial protection by brief ischemia in noncardiac tissue.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Vessels; Ganglia, Autonomic; Heart; H | 1996 |
Myocardial protection by brief ischemia in noncardiac tissue.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Vessels; Ganglia, Autonomic; Heart; H | 1996 |
Myocardial protection by brief ischemia in noncardiac tissue.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Vessels; Ganglia, Autonomic; Heart; H | 1996 |
Myocardial protection by brief ischemia in noncardiac tissue.
Topics: Animals; Arterial Occlusive Diseases; Blood Pressure; Coronary Vessels; Ganglia, Autonomic; Heart; H | 1996 |
Sites of action of adenosine in interorgan preconditioning of the heart.
Topics: Adenosine; Animals; Blood Pressure; Coronary Vessels; Ganglionic Blockers; Heart Rate; Hexamethonium | 2002 |